WuXi Biologics (Cayman) Inc. (HKG: 2269)

WuXi Biologics Revenue

WuXi Biologics had revenue of 8.57B CNY in the half year ending June 30, 2024, with 18.98% growth. This brings the company's revenue in the last twelve months to 17.12B, up 3.40% year-over-year. In the year 2023, WuXi Biologics had annual revenue of 17.03B with 11.56% growth.

• Revenue (ttm): 17.12B CNY
• Revenue Growth: +3.40%
• P/S Ratio: 4.21
• Revenue / Employee: 1.34M CNY
• Employees: 12,740
• Market Cap: 76.61B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	17.03B	1.77B	11.56%
Dec 31, 2022	15.27B	4.98B	48.38%
Dec 31, 2021	10.29B	4.68B	83.35%
Dec 31, 2020	5.61B	1.63B	40.88%
Dec 31, 2019	3.98B	1.45B	57.18%